Rhinogram vs Becton Dickinson

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (79 vs 35)
Rhinogram logo

Rhinogram

EmergingHealthTech

Patient Communication

Rhinogram is a HIPAA-compliant patient communication platform enabling healthcare providers to text, video chat, and send forms to patients using their existing office phone number.

AI VisibilityBeta
Overall Score
D35
Category Rank
#535 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
29
Gemini
31

About

Rhinogram provides healthcare practices with a HIPAA-compliant messaging platform that allows clinical and administrative staff to communicate with patients via text message, secure video, and digital forms using the practice's existing landline or VoIP phone number — without sharing personal staff cell numbers. Patients text the office number they already have, and staff manage all conversations through a unified web and mobile inbox that supports multiple simultaneous conversations, message templates, and team assignments.

Full profile
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B79
Category Rank
#24 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
82
Gemini
84

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

AI Visibility Head-to-Head

35
Overall Score
79
#535
Category Rank
#24
87
AI Consensus
77
stable
Trend
stable
31
ChatGPT
76
29
Perplexity
82
31
Gemini
84
34
Claude
84
34
Grok
77

Key Details

Category
Patient Communication
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Rhinogram
Patient Communication

Integrations

Only Becton Dickinson
Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.